---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-002609"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2022-04-15T23:59:59+00:00"
generated_at: "2026-06-26T07:04:01.039742+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Cytokinetics General Counsel Mark Schlossberg to retire May 13, 2022

## Summary
- Mark A. Schlossberg, SVP Legal, General Counsel and Secretary, announced retirement.
- Retirement effective May 13, 2022; departure on mutually good terms.
- No replacement has been named at this time.

## SEC filing metadata
- accession: 0001171843-22-002609
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2022-04-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000117184322002609/0001171843-22-002609-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000117184322002609/f8k_041522.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-002609
- JSON: https://secwatch.observer/filing/0001171843-22-002609.json
- Plain text: https://secwatch.observer/filing/0001171843-22-002609.txt

## Key facts
- Executive change
  Mark A. Schlossberg retired as Senior Vice President, Legal, General Counsel and Secretary at CYTOKINETICS INC.
  - Action: retired
  - Role: Senior Vice President, Legal, General Counsel and Secretary
  source text: On April 12, 2022, Mark A. Schlossberg, Senior Vice President, Legal, General Counsel and Secretary of Cytokinetics, Incorporated, informed Cytokinetics that he would be retiring from Cytokinetics effective May 13, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1061983/000117184322002609/0001171843-22-002609-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.